Comparison of the efficacy of a generic plerixafor versus Mozobil as adjunct peripheral blood stem cell mobilization agents in multiple myeloma patients.

Transfusion · 2024 · PMC11637246 · PMID 39367642

Europe PMC DOI

hedged sentence

0.0550

closest p · 1.1× alpha

0.0550

boldest claim

The sentences

nearly statistically significantp = .055so close (0.05 < p ≤ 0.1)

However, after the first dose of plerixafor, the generic cohort patients had a higher median PBCD34+ count (59.0/μL) compared to brand cohort patients (43.5/μL), and this difference was nearly statistically significant ( p = .055).

also in 78 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.